Bayer (BAYN) Corporate presentation summary

Strategic positioning and market overview

• Operates as a global leader in health and nutrition, with strong positions in crop science, pharmaceuticals, and consumer health, addressing fundamental human needs.

• Focuses on innovation, investing ~€6bn annually in R&D, and launching numerous new products across divisions.

• Responds to global megatrends such as aging and growing populations, climate change, and ecosystem pressures, shaping divisional missions.

• Implements a new operating model, Dynamic Shared Ownership, to drive efficiency, customer centricity, and innovation speed.

• Targets €2bn in sustainable organizational savings by end of 2026, supporting profitability and flexibility.

Financial performance and outlook

• 2025 net sales reached €45.6bn, with a core EPS of €4.91 and free cash flow of €2.1bn.

• EBITDA before special items declined due to lower topline, product mix changes, and inflationary pressures, but countermeasures and efficiency programs are in place.

• 2026 outlook projects net sales of €45.0–47.0bn and core EPS of €4.30–4.80, with significant litigation-related cash outflows impacting free cash flow.

• Strategic priorities include pharma growth, litigation containment, cash generation, deleveraging, and crop science profitability.

• Aims to improve credit rating to single A category and return to sales growth by 2027.

Crop science division

• Holds #1 global position in seeds & traits and crop protection, contributing ~20% of inputs to the global ag market.

• Targets above-market growth (~3% CAGR), mid-20% EBITDA margin by 2029, and >€3.5bn incremental net sales from innovation by 2029.

• Pipeline includes >€32bn peak sales potential, with ten blockbuster launches expected in the next decade.

• Annual refresh of 400–500 seed hybrids/varieties and 90–100 new crop protection formulations planned.

• Focuses on holistic crop system solutions and scaling regenerative agriculture.